Education
About Us
Working with TipRanks
Follow Us
Exact Sciences Corp. (EXAS)
NASDAQ:EXAS
Earnings Data
Report Date
Aug 05, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.12Last Year’s EPS
-0.09Same Quarter Last Year
Strong Buy
Based on 20 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 01, 2025
|% Change Since: 19.11%
|Next Earnings Date:Aug 05, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, improved profitability, and successful product launches, indicating a strong start to 2025. However, challenges with commercial payer coverage for new products and the impact of a severe flu season were noted.Company Guidance
During the recent earnings call, Exact Sciences provided guidance for 2025, highlighting several key metrics and growth drivers. The company expects total revenue for the year to be between $3.07 billion and $3.12 billion, an increase of $40 million at the midpoint, with second-quarter revenue projected to range from $765 million to $780 million. Screening revenue is anticipated to be between $2.39 billion and $2.425 billion for the year, while precision oncology revenue is forecasted to be between $680 million and $695 million. Additionally, Exact Sciences raised its adjusted EBITDA guidance to between $425 million and $455 million, reflecting an adjusted EBITDA margin of 14.2% at the midpoint. The company reported strong first-quarter results, with core revenue growth of 11%, adjusted EBITDA growth of 61%, and a 280 basis point expansion in adjusted EBITDA margin. Key growth drivers include the successful launch of Cologuard Plus, the expansion of the Rescreen program, and improvements in commercial execution, evidenced by a 30% increase in customer engagement and the addition of 190,000 new ordering providers.Strong Revenue Growth
Core revenue grew by 11%, with first-quarter revenue $19 million above the midpoint of guidance. Screening revenue increased by 14% to $540 million.
Improved Profitability
Adjusted EBITDA increased by 61% to $63 million, with an adjusted EBITDA margin expansion of 280 basis points.
Successful Product Launches
Launched Cologuard Plus with Medicare coverage and Oncodetect, a molecular residual disease test, positioned for growth in precision oncology.
Customer Satisfaction and Engagement
Customer satisfaction reached an all-time high in Q1, and customer engagement by the field force increased by more than 30% year-over-year.
Cash Flow Improvements
Free cash flow reached break-even, a year-over-year improvement of $120 million.
---
EXAS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
EXAS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 01, 2025 | $47.16 | $51.55 | +9.31% |
Feb 19, 2025 | $50.48 | $49.51 | -1.92% |
Nov 05, 2024 | $71.51 | $54.72 | -23.48% |
Jul 31, 2024 | $45.68 | $57.91 | +26.77% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Exact Sciences Corp. (EXAS) report earnings?
Exact Sciences Corp. (EXAS) is schdueled to report earning on Aug 05, 2025, TBA Not Confirmed.
What is Exact Sciences Corp. (EXAS) earnings time?
Exact Sciences Corp. (EXAS) earnings time is at Aug 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EXAS EPS forecast?
EXAS EPS forecast for the fiscal quarter 2025 (Q2) is -0.12.
---